Your shopping cart is currently empty

TRK-IN-29 (Compound B31) is a second-generation TRK inhibitor with IC50 values of 9 nM for TRKAG595R, 0.6 nM for TRKAF589L, 18 nM for TRKAG667C, 5 nM for TRKA, and 6 nM for TRKC. It effectively inhibits the phosphorylation of TRKA and demonstrates significant antiproliferative activity against NTRK fusion-positive cells. TRK-IN-29 also exhibits excellent plasma stability and moderate pharmacokinetic properties.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | TRK-IN-29 (Compound B31) is a second-generation TRK inhibitor with IC50 values of 9 nM for TRKAG595R, 0.6 nM for TRKAF589L, 18 nM for TRKAG667C, 5 nM for TRKA, and 6 nM for TRKC. It effectively inhibits the phosphorylation of TRKA and demonstrates significant antiproliferative activity against NTRK fusion-positive cells. TRK-IN-29 also exhibits excellent plasma stability and moderate pharmacokinetic properties. |
| In vitro | TRK-IN-29 exhibits significant antiproliferative activity against Km-12, Ba/F3-TRKA G595R, and Ba/F3-TRKA G667C cells, with IC50 values of 0.3, 4.7, and 9.9 nM, respectively. |
| Formula | C19H17F3N6O |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.